Elsborg L, Jørgensen F
Medical Dept. B, Central Hospital, Hillerød, Denmark.
Scand J Gastroenterol. 1991 Feb;26(2):146-50. doi: 10.3109/00365529109025024.
Sixty patients with endoscopically verified oesophagitis entered a double-blind clinical study comparing 1 g sucralfate granulate given four times daily and 400 mg cimetidine twice daily. The efficacy, as judged by endoscopy and the symptomatic response, were studied after 4, 8, and 12 weeks of treatment. Macroscopic healing of oesophagitis was defined as complete epithelialization of all oesophageal erosive lesions classified in accordance with Savary-Miller. Groups were comparable with regard to demographic data. The healing rate at 12 weeks' end point was 62% in the sucralfate group and 59% in the cimetidine group (NS). Half of the patients in both groups (NS) were relieved of symptoms. No adverse effects were recorded. Sucralfate and cimetidine appear to be equally efficient in the treatment of reflux oesophagitis.
60例经内镜证实患有食管炎的患者进入一项双盲临床研究,比较每日4次服用1g硫糖铝颗粒剂和每日2次服用400mg西咪替丁的疗效。在治疗4周、8周和12周后,根据内镜检查和症状反应来研究疗效。食管炎的宏观愈合定义为所有按照Savary-Miller分类的食管糜烂性病变完全上皮化。两组在人口统计学数据方面具有可比性。硫糖铝组在12周终点时的愈合率为62%,西咪替丁组为59%(无显著性差异)。两组中均有一半的患者(无显著性差异)症状得到缓解。未记录到不良反应。硫糖铝和西咪替丁在反流性食管炎的治疗中似乎同样有效。